First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
El 27 de abril, en celebración del Mes Nacional de la Historia de los Sordos, Disney+ estrenará Canciones en Lengua de Señas de Disney Animation, creadas en colaboración con Deaf West Theatre de Los ...
The MarketWatch News Department was not involved in the creation of this content. -- Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated ...
Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...
Following this weekend’s strong opening for Goat, Sony Pictures Animation will open its next original feature toon, Buds, on Wednesday, Dec. 22, 2027. The only other movie dated for Dec. 22 is a ...
Mr. Shinners is a pianist and harpsichordist and hosts the podcast “W.T.F. Bach.” See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda. Add ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...
Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...
Looking back on 2025 is like trying to recount a dream — a mix of dagger-sharp details and foggy stretches that fall apart when you try to apprehend them. I seem to remember some absurd plot twists ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results